Sector News

Amgen appoints senior VP and head of the European region

June 16, 2015
Life sciences
Amgen has named Corinne Le Goff as senior vice president and head of the European region.
 
Effective from June 1, Le Goff will be responsible for leading Amgen’s growth in Europe and will report directly to executive VP of global commercial operations, Anthony Hooper.
 
Commenting on her appointment, Le Goff said: “This is a pivotal moment for Amgen with a number of innovative new compounds either in the late stage clinical research or under review by the European regulatory authorities. 
 
“I am delighted to have the opportunity to lead the team in Europe at this exciting time.”
 
Le Goff joins from Roche, where she most recently served as president since 2012. In the role, she successfully led the business and a team of over 1,200 staff and helped evolve the business into one with a greater focus on market access and key account management.
 
Previously, Le Goff spent five years in strategic commercial leadership roles managing therapeutic areas at Roche, where she was senior VP of global product strategy for the neurosciences franchise and at Merck Serono, where she was senior VP of strategy and global marketing for neurology, rheumatology and immunology.
 
Hooper added: “Corinne brings strong vision and leadership to our European operations based on her broad strategic and operational experience in large healthcare organisations at both the global and affiliate level. I am delighted to welcome her to the team”.
 
Source: Amgen

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.